A rare proxy fight in Germany between an activist investor and the management of Stada Arzneimittel culminated with the departure of the German generic drugmaker’s supervisory board chairman following a marathon shareholder meeting.
from WSJ.com: US Business http://ift.tt/2bo3ewX
via IFTTT
No comments:
Post a Comment